Subscribe to our newsletter and stay informed

Check out our list of top companies

Check out our carefully compiled lists of the most relevant and impactful companies within their fields.

Check out our list of top unicorns

Read and learn about the biggest companies that various countries have produced, how they made it, and what the future looks like for them.
November 23, 2023

Linio Biotech Raises €4.2M Investment Boost to Revolutionize Tissue Regeneration

The Nordic wonder spearheaded by pioneering female minds, has clinched a stellar €4.2 million investment

In a groundbreaking move that echoes innovation, Finnish biotech trailblazer Linio Biotech has secured a substantial €4.2 million investment, catapulting its total funding to an impressive €9 million. This infusion of capital, featuring new Finnish private investors and industry-savvy doctors alongside existing supporters, propels Linio Biotech into a new phase of expansion. The company, born out of the University of Tampere in 2017, is poised to redefine tissue regeneration with its star product, Tience®.

Founded by the visionary duo Timo Ylikomi, professor of cell biology, and cell biologist and researcher Riina Uusmies, Linio Biotech is the brainchild of a spin-off from the University of Tampere. At the heart of their innovation lies Tience®, an injectable tissue product designed to simplify and democratize tissue regeneration. Unlike the conventional pace of the industry, Tience® stands out, offering professionals a natural and long-term solution for repairing skin defects such as aging signs and visible scars.

The latest funding injection will propel Linio Biotech to expand the reach of Tience® treatments, manufactured in the vibrant city of Tampere, Finland. Launched locally in June 2023, the company is on the brink of commercialization in other Nordic countries. With plans to attract further investors until the spring, Linio Biotech is setting its sights on global impact within the rapidly growing regenerative aesthetics niche, targeting the €40 billion aesthetics and scar healing market.

Linio Biotech's journey is a testament to the power of innovation in the biotech landscape. With a fresh wave of funding, Tience® is poised to not only revolutionize skin regeneration but also make waves in the global aesthetics market. The intersection of science, investment, and ambition marks Linio Biotech's commitment to transforming the industry. As CEO Karita Reijonsaari aptly puts it, the new funding is not just a financial boost; it's a commitment to maintaining an ambitious roadmap in the face of challenging investment climates. Brace yourselves for a new era in tissue regeneration, led by Linio Biotech and the game-changing Tience®.

Neil Hodgson Coyle
Neil Hodgson-Coyle
Editorial chief at TechNews180
Back to top

Related articles

chevron-down linkedin facebook pinterest youtube rss twitter instagram facebook-blank rss-blank linkedin-blank pinterest youtube twitter instagram